Webinar Date/Time: Thursday, March 21, 2024 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET
Real-world data (RWD) and real-world evidence (RWE) are playing increasingly important roles in healthcare and are making it possible for decision makers to gain insights and incorporate more data quickly into research decisions. Optimization of this data will enable researchers to design and conduct clinical trials more efficiently, both from a cost and timeline perspective. This webinar focuses on the significance of leveraging data management technology to increase collaboration amongst stakeholders and maximize the value derived from the data provided newer platforms.
Register Free: https://www.pharmexec.com/pe/rethink-reignite-reimagine
Event Overview:
Real-world data (RWD) and real-world evidence (RWE) are playing increasingly important roles in healthcare and are making it possible for decision makers to gain insights and incorporate more data quickly into research decisions. Optimization of this data will enable researchers to design and conduct clinical trials more efficiently, both from a cost and timeline perspective.
However, accessing and analyzing large amounts of data can be unwieldy and resource intensive. How do we ensure sponsors, sites, regulatory authorities, and study teams can efficiently and easily manage this wealth of new data to deliver actionable insights? And how can we streamline complex data sets into a single and actionable source of truth?
This webinar focuses on the significance of leveraging data management technology to increase collaboration amongst stakeholders and maximize the value derived from the data provided newer platforms.
Key Learning Objectives
Who Should Attend
This webinar is applicable to:
Full Agenda
Thursday, March 21st:
11:00 am EDT Unlocking Potential and Navigating Limitations of Using Real-World Evidence in Safety
Martina Furegato, Associate Principal; Oracle Life Sciences
Robert Weber, Product Management Director; Oracle Life Sciences
Elise Berliner, Global Senior Principal of Real-World Evidence Strategy; Oracle Life Sciences
12:00 pm EDT Taming the Data Tsunami From Decentralized Clinical Trials and Real-World Data
David Blackman, Executive Director Digital Trials Strategy; Oracle Life Sciences
1:00 pm EDT Creating the Future in Clinical Research with CROs Using Real-World Data
Speakers:
Martina Furegato
Associate Principal
Oracle Life Sciences
Robert Weber
Product Management Director
Oracle Life Sciences
Elise Berliner
Global Senior Principal of Real-World Evidence Strategy
Oracle Life Sciences
David Blackman
Executive Director Digital Trials Strategy
Oracle Life Sciences
Register Free: https://www.pharmexec.com/pe/rethink-reignite-reimagine
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Tirzepatide Demonstrates Significant Benefits for Patients with Pre-Diabetes, Obesity Over 176 Weeks
November 14th 2024Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.